| No. |
RNAi strategy used |
System tested |
Target region |
Reference |
| 1 |
Plasmid-encoded dual siRNAs |
In vitro |
3D |
57 |
| 2 |
19-mer siRNAs |
In vitro |
2A |
58 |
| 3 |
19-mer siRNAs |
In vitro and in vivo |
2A |
59 |
| 4 |
19-mer siRNAs |
In vitro |
3D |
60 |
| 5 |
19-mer siRNAs |
In vitro |
3D |
61 |
| 6 |
Plasmid-encoded shRNAs |
In vitro and in vivo |
3D and VP1 |
62 |
| 7 |
Plasmid-encoded shRNAs |
In vitro |
CAR gene coding for CVB3 receptor |
63 |
| 8 |
Viral-vector encoded shRNAs |
In vivo |
2C |
64 |
| 9 |
Viral-vector encoded shRNAs |
In vitro and in vivo |
3D |
65 |
| 10 |
19-mer siRNAs and siRNAs containing locked nucleic acids (LNAs) |
In vitro |
3D and 5′UTR |
66 |
| 11 |
siRNAs containing locked nucleic acids (LNAs) |
In vitro |
5′UTR |
67 |
| 12 |
Multiple 19-mer siRNAs |
In vitro |
3D |
68 |
| 13 |
19-mer siRNAs and plasmid-encoded siRNAs |
In vitro |
3D and CAR gene coding for CVB3 receptor |
69 |
